Skip to main content

Table 3 Summary statistics and main effects of treatment or HIV status in selected distributions

From: Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis

Variable & range (days) KI (0–2) b (2 onwards) KI(2–7) KI (7–14) KI (14–28) b (2–28) KI (2–28)
Mean* (& no. of patients) 0.513(87) 0.123 (75) 0.161 (68) 0.094 (60) 0.071 (43) 0.077 (44) 0.081 (44)
Standard deviation* 0.554 0.116 0.220 0.123 0.072 0.048 0.054
Mean* (& no. of patients):        
SHT 0.540 (49) 0.095 (44) 0.121 (42) 0.091 (38) 0.053 (26) 0.057 (27) 0.060 (27)
SHRZ 0.479 (38) 0.163 (31) 0.225 (26) 0.099 (22) 0.099 (17) 0.109 (17) 0.115 (17)
HIV- 0.526 (59) 0.099 (52) 0.124 (48) 0.086 (44) 0.072 (34) 0.076 (34) 0.079 (34)
HIV+ 0.486 (28) 0.177 (23) 0.250 (20) 0.114 (16) 0.066 (9) 0.080 (10) 0.087 (10)
2-way anova        
Treatment F (& p) 0.3 (0.6) 8.8 (0.004) 4.2 (0.044) 0.0(1.0) 2.7 (0.1) 14.4(0.0005) 9.9 (0.003)
HIV status F (& p) 0.01 (0.9) 7.7 (0.007) 4.1 (0.051) 0.4 (0.5) 0.1 (0.7) 0.01 (0.9) 0.20 (0.7)
  1. * Means and standard deviations of untransformed data. Transformed data for KI (0–2), KI (2–7) and for all values of b except b(2–14). All interactions between treatment and HIV status were not significant. Statistically significant main effects (p < 0.05) are in bold type.